



POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dasseux et al.

Confirmation No.: 1877

Serial No.: 10/743,287

Art Unit: 1614

Filed: December 23, 2003

Examiner: To be assigned

For: CYCLOALKYL-HYDROXYL
COMPOUNDS AND COMPOSITIONS
FOR CHOLESTEROL MANAGEMENT
AND RELATED USES

Attorney Docket No.: 10173-105-999

**POWER OF ATTORNEY BY ASSIGNEE
AND EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71
WITH STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned assignee of the entire interest in the above-identified subject application hereby appoints Practitioners at Customer Number 20583 all of Jones Day, whose address is 222 East 41st Street, New York, New York 10017, as its attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71, provided that, if any one of these attorneys ceases being affiliated with the law firm of Jones Day as partner, counsel, or employee, then the appointment of that attorney and all powers derived therefrom shall terminate on the date such attorney ceases being so affiliated.

Please direct all correspondence for this application to customer no. 20583.

Esperion Therapeutics, Inc. is the:

- ☐ Applicant/Inventor
☒ Assignee of record of the entire right, title, and interest. See 37 CFR 3.71.
(Statement under 37 CFR 3.73(b) is applicable)

Statement Under 37 C.F.R. 3.73(b)

Esperion Therapeutics, Inc. states that it is:

☒ the assignee of the entire right, title, and interest in the patent application identified above by virtue of:


- ☒ An assignment from the inventors in connection with the above-identified application, for which a copy thereof is attached.
☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.
[Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: Esperion Therapeutics, Inc.

Date: May 18, 2004 Signature: Roger S. Newton
Typed Name: ROGER S. NEWTON
Position/Title: EXECUTIVE VP



POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dasseux et al.

Confirmation No.: 1877

Serial No.: 10/743,287

Art Unit: 1614

Filed: December 23, 2003

Examiner: To be assigned

For: CYCLOALKYL-HYDROXYL
COMPOUNDS AND COMPOSITIONS
FOR CHOLESTEROL MANAGEMENT
AND RELATED USES

Attorney Docket No.: 10173-105-999

**POWER OF ATTORNEY BY ASSIGNEE
AND EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71
WITH STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned assignee of the entire interest in the above-identified subject application hereby appoints Practitioners at Customer Number 20583 all of Jones Day, whose address is 222 East 41st Street, New York, New York 10017, as its attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71, provided that, if any one of these attorneys ceases being affiliated with the law firm of Jones Day as partner, counsel, or employee, then the appointment of that attorney and all powers derived therefrom shall terminate on the date such attorney ceases being so affiliated.

Please direct all correspondence for this application to customer no. 20583.

Esperion Therapeutics, Inc. is the:

- ☐ Applicant/Inventor
☒ Assignee of record of the entire right, title, and interest. See 37 CFR 3.71.
(Statement under 37 CFR 3.73(b) is applicable)

Statement Under 37 C.F.R. 3.73(b)

Esperion Therapeutics, Inc. states that it is:

☒ the assignee of the entire right, title, and interest in the patent application identified above by virtue of:

- ☒ An assignment from the inventors in connection with the above-identified application, for which a copy thereof is attached.
☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.
[Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: Esperion Therapeutics, Inc.

Date: May 18, 2004 Signature: Roger S. Newton
Typed Name: ROGER S. NEWTON
Position/Title: EXECUTIVE VP